Cargando…

91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria

ABSTRACT IMPACT: This study aims to provide insight into naturally acquired immunity against severe malaria, thereby laying the foundation for the design of novel vaccine candidates to prevent severe disease as well as monoclonal antibody therapies to treat severe malaria. OBJECTIVES/GOALS: Severe m...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes, Raphael, Turner, Louise, Ssewanyana, Isaac, Rek, John, Greenhouse, Bryan, Bol, Sebastiaan, Lavstsen, Thomas, Bunnik, Evelien M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827713/
http://dx.doi.org/10.1017/cts.2021.451
_version_ 1784647693505658880
author Reyes, Raphael
Turner, Louise
Ssewanyana, Isaac
Rek, John
Greenhouse, Bryan
Bol, Sebastiaan
Lavstsen, Thomas
Bunnik, Evelien M.
author_facet Reyes, Raphael
Turner, Louise
Ssewanyana, Isaac
Rek, John
Greenhouse, Bryan
Bol, Sebastiaan
Lavstsen, Thomas
Bunnik, Evelien M.
author_sort Reyes, Raphael
collection PubMed
description ABSTRACT IMPACT: This study aims to provide insight into naturally acquired immunity against severe malaria, thereby laying the foundation for the design of novel vaccine candidates to prevent severe disease as well as monoclonal antibody therapies to treat severe malaria. OBJECTIVES/GOALS: Severe malaria is caused by parasite surface antigens that contain high sequence diversity. Nevertheless, P. falciparum-exposed individuals develop antibody responses against these antigens. Our goal is to isolate antibodies with broad reactivity to understand how disease protection is acquired. METHODS/STUDY POPULATION: Our study cohort consists of Ugandan adults living in a malaria-endemic region with high transmission intensity, who are protected against severe malaria. Using fluorescently labeled probes of parasite surface antigens, we have isolated antigen-specific B cells from these donors. We then expressed the corresponding monoclonal antibodies in vitro. These antibodies were screened against a library of variant surface antigens to determine antibody breadth and potential to inhibit interaction of the parasite surface antigen with host receptors, a critical step in pathogenesis. Additionally, using a panel of variant surface antigen mutants, we have predicted the epitopes targeted by the broadest monoclonal antibodies. RESULTS/ANTICIPATED RESULTS: We have identified three monoclonal antibodies with exceptionally broad reactivity and inhibitory activity against our panel of severe disease-inducing variant surface antigens. We have identified two major sites targeted by these broadly reactive antibodies. The first site was associated with the largest breadth, but limited inhibitory potential, while the second site showed high-affinity antibody binding and inhibition of receptor binding. Interestingly, two of these three antibodies were very similar in structure, even though they were isolated from different donors. Isolation of antigen-specific B cells from additional donors will enable us to identify how common such broadly reactive antibodies are and allow the identification of additional epitopes DISCUSSION/SIGNIFICANCE OF FINDINGS: This study is the first to isolate broadly reactive antibodies that are likely to protect against severe malaria in naturally immune individuals. Further characterization of antibody-antigen interactions will inform the development of this surface antigen as a vaccine candidate for malaria.
format Online
Article
Text
id pubmed-8827713
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-88277132022-02-28 91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria Reyes, Raphael Turner, Louise Ssewanyana, Isaac Rek, John Greenhouse, Bryan Bol, Sebastiaan Lavstsen, Thomas Bunnik, Evelien M. J Clin Transl Sci Basic Science ABSTRACT IMPACT: This study aims to provide insight into naturally acquired immunity against severe malaria, thereby laying the foundation for the design of novel vaccine candidates to prevent severe disease as well as monoclonal antibody therapies to treat severe malaria. OBJECTIVES/GOALS: Severe malaria is caused by parasite surface antigens that contain high sequence diversity. Nevertheless, P. falciparum-exposed individuals develop antibody responses against these antigens. Our goal is to isolate antibodies with broad reactivity to understand how disease protection is acquired. METHODS/STUDY POPULATION: Our study cohort consists of Ugandan adults living in a malaria-endemic region with high transmission intensity, who are protected against severe malaria. Using fluorescently labeled probes of parasite surface antigens, we have isolated antigen-specific B cells from these donors. We then expressed the corresponding monoclonal antibodies in vitro. These antibodies were screened against a library of variant surface antigens to determine antibody breadth and potential to inhibit interaction of the parasite surface antigen with host receptors, a critical step in pathogenesis. Additionally, using a panel of variant surface antigen mutants, we have predicted the epitopes targeted by the broadest monoclonal antibodies. RESULTS/ANTICIPATED RESULTS: We have identified three monoclonal antibodies with exceptionally broad reactivity and inhibitory activity against our panel of severe disease-inducing variant surface antigens. We have identified two major sites targeted by these broadly reactive antibodies. The first site was associated with the largest breadth, but limited inhibitory potential, while the second site showed high-affinity antibody binding and inhibition of receptor binding. Interestingly, two of these three antibodies were very similar in structure, even though they were isolated from different donors. Isolation of antigen-specific B cells from additional donors will enable us to identify how common such broadly reactive antibodies are and allow the identification of additional epitopes DISCUSSION/SIGNIFICANCE OF FINDINGS: This study is the first to isolate broadly reactive antibodies that are likely to protect against severe malaria in naturally immune individuals. Further characterization of antibody-antigen interactions will inform the development of this surface antigen as a vaccine candidate for malaria. Cambridge University Press 2021-03-30 /pmc/articles/PMC8827713/ http://dx.doi.org/10.1017/cts.2021.451 Text en © The Association for Clinical and Translational Science 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic Science
Reyes, Raphael
Turner, Louise
Ssewanyana, Isaac
Rek, John
Greenhouse, Bryan
Bol, Sebastiaan
Lavstsen, Thomas
Bunnik, Evelien M.
91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria
title 91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria
title_full 91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria
title_fullStr 91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria
title_full_unstemmed 91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria
title_short 91074 Identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria
title_sort 91074 identification of monoclonal antibodies with broad reactivity against the malaria parasite variant surface antigen responsible for severe malaria
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827713/
http://dx.doi.org/10.1017/cts.2021.451
work_keys_str_mv AT reyesraphael 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria
AT turnerlouise 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria
AT ssewanyanaisaac 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria
AT rekjohn 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria
AT greenhousebryan 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria
AT bolsebastiaan 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria
AT lavstsenthomas 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria
AT bunnikevelienm 91074identificationofmonoclonalantibodieswithbroadreactivityagainstthemalariaparasitevariantsurfaceantigenresponsibleforseveremalaria